Gene · 407014
Papers3,611
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
581 to 600 of 3,611
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Human platelet lysate-derived extracellular vesicles enhance angiogenesis through miR-126. | Cell Prolif | 2022 | 35946052 | PubTator, text mining | PubMed |
| A previously unknown Argonaute 2 variant positively modulates the viability of melanoma cells. | Cell Mol Life Sci | 2022 | 35943635 | PubTator, text mining | PubMed |
| The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer. | Front Oncol | 2022 | 35936737 | PubTator, text mining | PubMed |
| The emerging role of miRNAs in the pathogenesis of COVID-19: Protective effects of nutraceutical polyphenolic compounds against SARS-CoV-2 infection. | Int J Med Sci | 2022 | 35928726 | PubTator, text mining | PubMed |
| Bidirectional cytokine-microRNA control: A novel immunoregulatory framework in leishmaniasis. | PLoS Pathog | 2022 | 35925884 | PubTator, text mining | PubMed |
| The Key Role of microRNAs in Initiation and Progression of Hepatocellular Carcinoma. | Front Oncol | 2022 | 35924150 | PubTator, text mining | PubMed |
| Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow. | Front Mol Biosci | 2022 | 35923465 | PubTator, text mining | PubMed |
| Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment. | Cell Mol Biol Lett | 2022 | 35922753 | PubTator, text mining | PubMed |
| Treatment of ischemic stroke with modified mesenchymal stem cells. | Int J Med Sci | 2022 | 35919816 | PubTator, text mining | PubMed |
| Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma. | Front Oncol | 2022 | 35912267 | PubTator, text mining | PubMed |
| Evidence for the circulating microRNA hsa-let-7d-3p as a potential new biomarker for sepsis in human subjects. | Eur J Med Res | 2022 | 35907902 | PubTator, text mining | PubMed |
| Possible relation between expression of circulating microRNA and plasma cytokine levels in cases of pulmonary tuberculosis. | J Infect Dev Ctries | 2022 | 35905021 | PubTator, text mining | PubMed |
| Progression of Type 1 Diabetes: Circulating MicroRNA Expression Profiles Changes from Preclinical to Overt Disease. | J Immunol Res | 2022 | 35903753 | PubTator, text mining | PubMed |
| Hsa-let-7c-5p, hsa-miR-130b-3p, and hsa-miR-142-3p as Novel miRNA Biomarkers for Melanoma Progression. | Genet Res (Camb) | 2022 | 35903462 | PubTator, text mining | PubMed |
| Performance of Salivary Extracellular RNA Biomarker Panels for Gastric Cancer Differs between Distinct Populations. | Cancers (Basel) | 2022 | 35892889 | PubTator, text mining | PubMed |
| Tracking an Elusive Killer: State of the Art of Molecular-Genetic Knowledge and Laboratory Role in Diagnosis and Risk Stratification of Thoracic Aortic Aneurysm and Dissection. | Diagnostics (Basel) | 2022 | 35892496 | PubTator, text mining | PubMed |
| Current Concepts of Vitiligo Immunopathogenesis. | Biomedicines | 2022 | 35884944 | PubTator, text mining | PubMed |
| MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes. | Cancers (Basel) | 2022 | 35884580 | PubTator, text mining | PubMed |
| Circulating Exosome Cargoes Contain Functionally Diverse Cancer Biomarkers: From Biogenesis and Function to Purification and Potential Translational Utility. | Cancers (Basel) | 2022 | 35884411 | PubTator, text mining | PubMed |
| Differential Expression of Serum Exosomal Hsa-miR-487b-3p in Progressive Vitiligo Before and After Systemic Corticosteroid Treatment. | Clin Cosmet Investig Dermatol | 2022 | 35880009 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/407014/papers?page=30